FBXO22 is a potential therapeutic target for recurrent chondrosarcoma

Baoquan Xin; Hui Chen; Zhi Zhu; Qiujing Guan; Guangjian Bai; Cheng Yang; WeiWei Zou; Xin Gao; Lei Li; Tielong Liu

doi:10.1016/j.jbo.2024.100605

FBXO22 is a potential therapeutic target for recurrent chondrosarcoma

J Bone Oncol. 2024 May 1:46:100605. doi: 10.1016/j.jbo.2024.100605. eCollection 2024 Jun.

Authors

Baoquan Xin^{1

2}, Hui Chen³, Zhi Zhu⁴, Qiujing Guan⁵, Guangjian Bai^{1

2}, Cheng Yang², WeiWei Zou⁶, Xin Gao², Lei Li^{3

5}, Tielong Liu²

Affiliations

¹ School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, 200003, China.
² Department of Orthopaedic Oncology, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.
³ Joint Center for Translational Medicine, Shanghai Fifth People's Hospital, Fudan University and School of Life Science, East China Normal University, Shanghai, 200241, China.
⁴ Department of Pathology, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.
⁵ Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China.
⁶ Department of Medical Imaging, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.

Abstract

Chondrosarcoma (CHS) is a malignant bone tumor with insensitivity to both radiotherapy and chemotherapy, and a high recurrence rate. However, the latent mechanism of recurrent CHS (Re-CHS) remains elusive. Here, we discovered that FBXO22 was highly expressed in clinical samples of Re-CHS. FBXO22 played a significant role in various cancers. However, the role of FBXO22 in Re-CHS remained unclear. Our research demonstrated that suppressing FBXO22 abated the proliferation and migration of CHS cells and facilitated their apoptosis. In addition, suppressing FBXO22 raised the expression of PD-L1 in Re-CHS. All these findings provide new evidence for using FBXO22 and PD-L1 as combined targets to prevent and treat Re-CHS, which may prove to be a novel strategy for immunotherapy of CHS, especially Re-CHS.

Keywords: Bone tumor; Chondrosarcoma; PD-L1; Recurrence; Therapeutic target.